Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group

Details

Ressource 1Download: serval:BIB_1676C07DC4D8.P001 (1403.11 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_1676C07DC4D8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group
Journal
European Heart Journal
Author(s)
Kappenberger L., Linde C., Daubert C., McKenna W., Meisel E., Sadoul N., Chojnowska L., Guize L., Gras D., Jeanrenaud X., Ryden L.
ISSN
0195-668X (Print)
Publication state
Published
Issued date
08/1997
Volume
18
Number
8
Pages
1249-56
Language
english
Notes
Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Aug
Abstract
BACKGROUND: Uncontrolled studies have shown that short atrioventricular delay dual chamber pacing reduces outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Although the exact mechanism of this beneficial effect is unclear, this seems a promising potential new treatment for hypertrophic obstructive cardiomyopathy. METHOD: In order to evaluate the impact of pacing therapy, were performed a randomized multicentre double-blind cross-over (pacemaker activated vs non activated) study to investigate modification of echocardiography, exercise tolerance, angina, dyspnoea and quality of life in 83 patients with a mean age of 53 (range 22-87) years with symptoms refractory or intolerant to classical drug treatment. RESULTS: After 12 weeks of activated or inactivated pacing, independent of which phase was first, the pressure gradient fell from 59 +/- 36 mmHg to 30 +/- 25 mmHg (P < 0.001) with active pacing. Exercise tolerance improved by 21% in those patients who at baseline tolerated less than 10 min of Bruce protocol; symptoms of dyspnoea and angina also improved significantly from NYHA class 2.4 to 1.4 and 1.0 to 0.4, respectively (P < 0.007). Quality of life assessment with a validated questionnaire objectivated the subjective improvement. CONCLUSION: Pacemaker therapy is of clinical and haemodynamic benefit for patients with hypertrophic obstructive cardiomyopathy, left ventricular outflow gradient at rest over 30 mmHg who are symptomatic despite drug treatment.
Keywords
Adult Aged Aged, 80 and over *Cardiac Pacing, Artificial Cardiomyopathy, Hypertrophic/*therapy Cross-Over Studies Double-Blind Method Exercise Tolerance Humans Middle Aged Prospective Studies Statistics, Nonparametric
Pubmed
Web of science
Open Access
Yes
Create date
15/02/2008 11:29
Last modification date
25/09/2019 6:08
Usage data